Strides Arcolab receives 2 more NDA approvals from US-FDA

Strides Arcolab Ltd on June 06, 2007 has announced that it has received tentative approvals from the United States - Food and Drug Administration for two new drug applications (NDA) for fixed dose combination of:

- Lamivudine/Stavudine 150 mg/40 mg tablets co-packaged with Efavirenz 600mg tablets And

- Lamivudine/Zidovudine 150/300 mg tablets co-packaged with Efavirenz 600mg tablets

both under the expedited review provisions of the President's Emergency Plan for Aids Relief (PEPFAR) program. This takes the total NDAs/ANDAs approvals received to 9 under the PEPFAR program.

Arun Kumar - Vice Chairman and Managing Director of the Company said "we now have approvals for all key front line HIV/AIDS medicines. This, combined with our pipeline of second line drugs, will make us a significant player in the quality, affordable multi-source ARVs business segment"

The Company also partners with the Clinton Foundation to ensure availability of affordable quality generic ARVs in least-developed countries.

The stock closed the day at Rs.357, up by Rs.3.80 or 1.08%. The stock hit an intraday high of Rs.366 and low of Rs.351. The total traded quantity was 82971 compared to 2 week average of 25515.

Source : Equity Bulls

Keywords